Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells

Cell Communication and Signaling

Volumn 6, Issue , 2008, Pages

  Aleksic, Tamara ^a   Feller, Stephan M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449126264     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/1478-811X-6-8     Document Type: Article

References (47)

1. Notch signalling: a simple pathway becomes complex. SJ Bray, Nat Rev Mol Cell Biol 2006 7 9 678 689 10.1038/nrm2009 16921404 (Pubitemid 44268213)
2. Notch signals control the fate of immature progenitor cells in the intestine. S Fre, M Huyghe, P Mourikis, S Robine, D Louvard, S Artavanis-Tsakonas, Nature 2005 435 7044 964 968 10.1038/nature03589 15959516 (Pubitemid 40896323)
3. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. C Grabher, H von Boehmer, AT Look, Nat Rev Cancer 2006 6 5 347 359 10.1038/nrc1880 16612405
4. Self-renewal and cancer of the gut: two sides of a coin. F Radtke, H Clevers, Science 2005 307 5717 1904 1909 10.1126/science.1104815 15790842 (Pubitemid 40404692)
5. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. JH van Es, ME van Gijn, O Riccio, M van den Born, M Vooijs, H Begthel, M Cozijnsen, S Robine, DJ Winton, F Radtke, H Clevers, Nature 2005 435 7044 959 963 10.1038/nature03659 15959515 (Pubitemid 40896322)
6. The Notch 'gospel'. F Radtke, F Schweisguth, W Pear, EMBO Rep 2005 6 12 1120 1125 16299468 10.1038/sj.embor.7400585 (Pubitemid 41741693)
7. Notch signaling in gastrointestinal tract (review). M Katoh, Int J Oncol 2007 30 1 247 251 17143535
8. Notch signaling: control of cell communication and cell fate. EC Lai, Development 2004 131 5 965 973 10.1242/dev.01074 14973298 (Pubitemid 38380451)
9. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. C Osipo, TE Golde, BA Osborne, LA Miele, Lab Invest 2008 88 1 11 17 10.1038/labinvest.3700700 18059366
10. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. D Selkoe, R Kopan, Annu Rev Neurosci 2003 26 565 597 10.1146/annurev.neuro.26.041002.131334 12730322 (Pubitemid 37064944)
11. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. CL Curry, LL Reed, TE Golde, L Miele, BJ Nickoloff, KE Foreman, Oncogene 2005 24 42 6333 6344 15940249 (Pubitemid 41486467)
12. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. BJ Nickoloff, BA Osborne, L Miele, Oncogene 2003 22 42 6598 6608 10.1038/sj.onc.1206758 14528285 (Pubitemid 37372340)
13. Notch signaling, gamma-secretase inhibitors, and cancer therapy. M Shih Ie, TL Wang, Cancer Res 2007 67 5 1879 1882 10.1158/0008-5472.CAN-06-3958 17332312 (Pubitemid 46424200)
14. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. JH van Es, H Clevers, Trends Mol Med 2005 11 11 496 502 10.1016/j.molmed.2005.09.008 16214417 (Pubitemid 41653290)
15. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. J Milano, J McKay, C Dagenais, L Foster-Brown, F Pognan, R Gadient, RT Jacobs, A Zacco, B Greenberg, PJ Ciaccio, Toxicol Sci 2004 82 1 341 358 10.1093/toxsci/kfh254 15319485 (Pubitemid 39485346)
16. Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells. M Emaduddin, DC Bicknell, WF Bodmer, SM Feller, Proc Natl Acad Sci USA 2008 105 7 2358 2362 18258742 10.1073/pnas.0712176105 (Pubitemid 351520518)
17. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. DW Nicholson, A Ali, NA Thornberry, JP Vaillancourt, CK Ding, M Gallant, Y Gareau, PR Griffin, M Labelle, YA Lazebnik, et al. Nature 1995 376 6535 37 43 10.1038/376037a0 7596430
18. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. M Tewari, LT Quan, K O'Rourke, S Desnoyers, Z Zeng, DR Beidler, GG Poirier, GS Salvesen, VM Dixit, Cell 1995 81 5 801 809 10.1016/0092-8674(95)90541-3 7774019
19. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. PJ Roberts, CJ Der, Oncogene 2007 26 22 3291 3310 10.1038/sj.onc.1210422 17496923 (Pubitemid 46763022)
20. MAP kinase signalling pathways in cancer. AS Dhillon, S Hagan, O Rath, W Kolch, Oncogene 2007 26 22 3279 3290 10.1038/sj.onc.1210421 17496922 (Pubitemid 46763021)
21. AKT/PKB signaling: navigating downstream. BD Manning, LC Cantley, Cell 2007 129 7 1261 1274 10.1016/j.cell.2007.06.009 17604717 (Pubitemid 46962095)
22. The BCL-2 protein family: opposing activities that mediate cell death. RJ Youle, A Strasser, Nat Rev Mol Cell Biol 2008 9 1 47 59 10.1038/nrm2308 18097445
23. Mitogen-activated protein kinase pathways. MJ Robinson, MH Cobb, Curr Opin Cell Biol 1997 9 2 180 186 10.1016/S0955-0674(97)80061-0 9069255 (Pubitemid 27135985)
24. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. S Schweyer, A Soruri, O Meschter, A Heintze, F Zschunke, N Miosge, P Thelen, T Schlott, HJ Radzun, A Fayyazi, Br J Cancer 2004 91 3 589 598 10.1038/sj.bjc.6601919 15266324 (Pubitemid 39093583)
25. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. S Singh, AK Upadhyay, AK Ajay, MK Bhat, FEBS Lett 2007 581 2 289 295 10.1016/j.febslet.2006.12.035 17208232 (Pubitemid 46110832)
26. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. D Tang, D Wu, A Hirao, JM Lahti, L Liu, B Mazza, VJ Kidd, TW Mak, AJ Ingram, J Biol Chem 2002 277 15 12710 12717 10.1074/jbc.M111598200 11821415 (Pubitemid 34952631)
27. The stress-activated protein kinase pathways. LA Tibbles, JR Woodgett, Cell Mol Life Sci 1999 55 10 1230 1254 10.1007/s000180050369 10487205 (Pubitemid 29410745)
28. Requirement for ERK activation in cisplatin-induced apoptosis. X Wang, JL Martindale, NJ Holbrook, J Biol Chem 2000 275 50 39435 39443 10.1074/jbc.M004583200 10993883 (Pubitemid 32058968)
29. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Hayakawa, M Ohmichi, H Kurachi, H Ikegami, A Kimura, T Matsuoka, H Jikihara, D Mercola, Y Murata, J Biol Chem 1999 274 44 31648 31654 10.1074/jbc.274.44.31648 10531373 (Pubitemid 29508533)
30. Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation. Its implication in an anti-apoptotic function. D Kitagawa, S Tanemura, S Ohata, N Shimizu, J Seo, G Nishitai, T Watanabe, K Nakagawa, H Kishimoto, T Wada, T Tezuka, T Yamamoto, H Nishina, T Katada, J Biol Chem 2002 277 1 366 371 10.1074/jbc.M107110200 11694531 (Pubitemid 34952067)
31. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. DL Persons, EM Yazlovitskaya, W Cui, JC Pelling, Clin Cancer Res 1999 5 5 1007 1014 10353733 (Pubitemid 29233214)
32. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Z Xia, M Dickens, J Raingeaud, RJ Davis, ME Greenberg, Science 1995 270 5240 1326 1331 10.1126/science.270.5240.1326 7481820
33. Systemic therapy for colorectal cancer. JA Meyerhardt, RJ Mayer, N Engl J Med 2005 352 5 476 487 10.1056/NEJMra040958 15689586 (Pubitemid 40175974)
34. Cellular and molecular pharmacology of oxaliplatin. E Raymond, S Faivre, S Chaney, J Woynarowski, E Cvitkovic, Mol Cancer Ther 2002 1 3 227 235 12467217
35. Cisplatin: mode of cytotoxic action and molecular basis of resistance. ZH Siddik, Oncogene 2003 22 47 7265 7279 10.1038/sj.onc.1206933 14576837 (Pubitemid 37487159)
36. Emerging therapies for colorectal cancer. AF Hezel, DP Ryan, Expert Opin Investig Drugs 2007 16 6 867 876 10.1517/13543784.16.6.867 17501698 (Pubitemid 46887127)
37. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. FM Johnson, GE Gallick, Anticancer Agents Med Chem 2007 7 6 651 659 10.2174/187152007784111278 18045060 (Pubitemid 350237770)
38. Novel targets for anticancer treatment development in colorectal cancer. T Macarulla, FJ Ramos, J Capdevila, C Saura, J Tabernero, Clin Colorectal Cancer 2006 6 4 265 272 10.3816/CCC.2006.n.045 17241511 (Pubitemid 46157476)
39. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. M Galanski, BK Keppler, Anticancer Agents Med Chem 2007 7 1 55 73 10.2174/187152007779314017 17266505 (Pubitemid 46062405)
40. Isolation of rare circulating tumour cells in cancer patients by microchip technology. S Nagrath, LV Sequist, S Maheswaran, DW Bell, D Irimia, L Ulkus, MR Smith, EL Kwak, S Digumarthy, A Muzikansky, P Ryan, UJ Balis, RG Tompkins, DA Haber, M Toner, Nature 2007 450 7173 1235 1239 10.1038/nature06385 18097410
41. Notch emerges as new cancer drug target. K Garber, J Natl Cancer Inst 2007 99 17 1284 1285 10.1093/jnci/djm148 17728207
42. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. S Weijzen, P Rizzo, M Braid, R Vaishnav, SM Jonkheer, A Zlobin, BA Osborne, S Gottipati, JC Aster, WC Hahn, M Rudolf, K Siziopikou, WM Kast, L Miele, Nat Med 2002 8 9 979 986 10.1038/nm754 12185362 (Pubitemid 35033702)
43. Ras pathway signals are required for notch-mediated oncogenesis. K Fitzgerald, A Harrington, P Leder, Oncogene 2000 19 37 4191 4198 10.1038/sj.onc.1203766 10980592
44. Notch signaling induces cell cycle arrest in small cell lung cancer cells. V Sriuranpong, MW Borges, RK Ravi, DR Arnold, BD Nelkin, SB Baylin, DW Ball, Cancer Res 2001 61 7 3200 3205 11306509 (Pubitemid 32691976)
45. Nuclear signaling by receptor tyrosine kinases: the first robin of spring. J Schlessinger, MA Lemmon, Cell 2006 127 1 45 48 10.1016/j.cell.2006.09. 013 17018275 (Pubitemid 44466641)
46. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. B McElroy, JC Powell, JV McCarthy, Biochem Biophys Res Commun 2007 358 4 1136 1141 10.1016/j.bbrc.2007. 05.062 17524361 (Pubitemid 46829007)
47. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. KS Vetrivel, H Cheng, SH Kim, Y Chen, NY Barnes, AT Parent, SS Sisodia, G Thinakaran, J Biol Chem 2005 280 27 25892 25900 15886206 10.1074/jbc.M503570200 (Pubitemid 40962301)